{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:47Z","timestamp":1785117587083,"version":"3.55.0"},"reference-count":150,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable clinical efficacy in hematological malignancies, yet their broader application is constrained by manufacturing complexity and variability, particularly in autologous settings. The development of allogeneic CAR T-cell therapies offers a promising alternative by enabling scalable, \u201coff-the-shelf\u201d production; however, these approaches introduce additional challenges related to donor variability, genome editing, and product consistency. Robust analytical strategies are therefore required to ensure safety, efficacy, and batch-to-batch reproducibility. Conventional analytical methods, such as flow cytometry and enzyme-linked immunosorbent assays, provide targeted, high-confidence measurements of predefined cellular and soluble markers but are inherently limited in their ability to capture the full molecular and functional complexity of CAR T-cell products. In current manufacturing paradigms, these assays are typically deployed as isolated quality control readouts rather than as components of an integrated control strategy that links donor variability, gene-editing material quality, in-process metabolic state, final product critical quality attributes, and clinical biomarker responses. In this context, mass spectrometry (MS) has emerged as a powerful platform for high-dimensional molecular characterization, enabling analysis of gene-editing reagents, proteins, metabolites, lipids, and both culture and spent-media composition across the CAR T-cell manufacturing workflow. In this review, we examine the various applications and tools of MS across key stages of the allogeneic CAR T-cell workflow, including donor characterization, analysis of gene-editing materials, in-process culture monitoring, drug product quality assessment, and post-infusion biomarker evaluation. Collectively, these approaches demonstrate the potential of MS-driven analytics to address current limitations in CAR T-cell manufacturing by improving process understanding, enabling comprehensive quality assessment, and supporting regulatory decision-making. The integration of MS into CAR T-cell workflows may ultimately facilitate the development of more consistent, scalable, and effective cell therapies.<\/jats:p>","DOI":"10.3390\/cells15151333","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:26:23Z","timestamp":1785115583000},"page":"1333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mass Spectrometry in Allogeneic CAR-T Cell Manufacturing: From Cellular Starting Materials to Multi-Attribute Quality Control"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8078-2279","authenticated-orcid":false,"given":"Naryeong","family":"Kim","sequence":"first","affiliation":[{"name":"Cell Therapy Engineering and Development, Genentech South San Francisco, 1 DNA Way, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0335-2020","authenticated-orcid":false,"given":"Zhouyang","family":"Huang","sequence":"additional","affiliation":[{"name":"Cell Therapy Engineering and Development, Genentech South San Francisco, 1 DNA Way, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Born","sequence":"additional","affiliation":[{"name":"Cell Therapy Engineering and Development, Genentech San Diego, 9390 Towne Centre Dr., San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-2278","authenticated-orcid":false,"given":"Julien","family":"Camperi","sequence":"additional","affiliation":[{"name":"Cell Therapy Engineering and Development, Genentech South San Francisco, 1 DNA Way, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","unstructured":"U.S. Food and Drug Administration (FDA) (2026, June 30). August 30, 2017 Approval Letter-KYMRIAH, Available online: https:\/\/www.fda.gov\/media\/106989\/download?attachment."},{"key":"ref_2","unstructured":"U.S. Food and Drug Administration (FDA) (2026, June 30). October 18, 2017 Approval Letter-YESCARTA, Available online: https:\/\/www.fda.gov\/media\/108458\/download?attachment."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"Lu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-Shelf\u2019 Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100677","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging Trends in Clinical Allogeneic CAR Cell Therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jtct.2025.09.044","article-title":"Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies","volume":"32","author":"Cheema","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing Graft-versus-Host Disease in Allogeneic Cell-Based Immunotherapy for Cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","article-title":"Genome-Edited Allogeneic CAR-T Cells: The next Generation of Cancer Immunotherapies","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.ejcped.2024.100149","article-title":"Genome Editing Approaches for Universal Chimeric Antigen Receptor T Cells","volume":"3","author":"Mishra","year":"2024","journal-title":"EJC Paediatr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-24-0482","article-title":"Regulatory Considerations for Genome-Edited T-Cell Therapies","volume":"12","author":"Jadlowsky","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (FDA) (2024). Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (FDA) (2025). Assessing Genetic Heterogeneity in the Context of Gene-Edited Products."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e006596","DOI":"10.1136\/jitc-2022-006596","article-title":"CAR T-Cell Detection Scoping Review: An Essential Biomarker in Critical Need of Standardization","volume":"11","author":"Turicek","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shao, L., Zheng, Y., Somerville, R.P., Stroncek, D.F., and Jin, P. (2025). New Insights on Potency Assays from Recent Advances and Discoveries in CAR T-Cell Therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1597888"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70012","DOI":"10.1049\/htl2.70012","article-title":"An Analysis of Monitoring Solutions for CAR T Cell Production","volume":"12","author":"Shoshi","year":"2025","journal-title":"Healthc. Technol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.4254","article-title":"Comparison of Mass Spectrometry and Flow Cytometry in Measuring Minimal Residual Disease in Multiple Myeloma","volume":"10","author":"Foureau","year":"2021","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lombard-Banek, C., and Schiel, J.E. (2020). Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies. Molecules, 25.","DOI":"10.3390\/molecules25061396"},{"key":"ref_18","unstructured":"Lau, H., and Rogers, R. (2021). Mass Spectrometry\u2013Based Process Analytical Technologies for Cell Therapies. LCGC N. Am., 39, Available online: https:\/\/www.chromatographyonline.com\/view\/mass-spectrometry-based-process-analytical-technologies-for-cell-therapies."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1021\/pr500753r","article-title":"Analytical Validation Considerations of Multiplex Mass-Spectrometry-Based Proteomic Platforms for Measuring Protein Biomarkers","volume":"13","author":"Boja","year":"2014","journal-title":"J. Proteome Res."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (FDA) (2026, June 30). Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","article-title":"Concise Review: Process Development Considerations for Cell Therapy","volume":"4","author":"Campbell","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"ref_22","unstructured":"(2026, June 30). Cell and Gene Therapy Answers: Assessing the Critical Quality Attributes, Challenges and Importance of CMC. Available online: https:\/\/www.labcorp.com\/education-events\/articles\/cell-and-gene-therapy-answers-assessing-critical-quality-attributes-challenges-and-importance-cmc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy","volume":"2","author":"Elsallab","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e20230903","DOI":"10.1084\/jem.20230903","article-title":"CAR-T Cell Manufacturing: Major Process Parameters and next-Generation Strategies","volume":"221","author":"Khericha","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41409-025-02637-8","article-title":"Harmonisation of Quality Control Tests for Academic Production of CAR-T Cells: A Position Paper from the WP-Bioproduction of the UNITC Consortium","volume":"60","author":"Marton","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing Chimeric Antigen Receptor T Cells: Issues and Challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis Guidance and Best Practices for Optimal Chimeric Antigen Receptor T-Cell Manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1021\/acs.jproteome.4c00930","article-title":"A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management","volume":"24","author":"Teibo","year":"2025","journal-title":"J. Proteome Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC Locus with CRISPR\/Cas9 Enhances Tumour Rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid Manufacturing of Non-Activated Potent CAR T Cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_34","unstructured":"U.S. Food and Drug Administration (FDA) (2026, June 30). Cellular & Gene Therapy Guidances, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/cellular-gene-therapy-guidances."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","article-title":"CAR-T Cell Expansion Platforms Yield Distinct T Cell Differentiation States","volume":"26","author":"Song","year":"2024","journal-title":"Cytotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hood, T., Slingsby, F., Sandner, V., Geis, W., Schmidberger, T., Bevan, N., Vicard, Q., Hengst, J., Springuel, P., and Dianat, N. (2024). A Quality-by-Design Approach to Improve Process Understanding and Optimise the Production and Quality of CAR-T Cells in Automated Stirred-Tank Bioreactors. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1335932"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e10753","DOI":"10.1002\/btm2.10753","article-title":"Establishing a Scalable Perfusion Strategy for the Manufacture of CAR-T Cells in Stirred-tank Bioreactors Using a Quality-by-design Approach","volume":"10","author":"Hood","year":"2025","journal-title":"Bioeng. Transla Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.omtm.2025.101613","article-title":"From Cold Chain to Ambient: Benefits, Risks, and Evidence across Cell Therapy Logistics","volume":"33","author":"Gostage","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Browne, D.J., Miller, C.M., and Doolan, D.L. (2024). Technical Pitfalls When Collecting, Cryopreserving, Thawing, and Stimulating Human T-Cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1382192"},{"key":"ref_40","unstructured":"U.S. Food and Drug Administration, and Center for Biologics Evaluation and Research (2026, March 17). Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/eligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","article-title":"Enriching Leukapheresis Improves T Cell Activation and Transduction Efficiency during CAR T Processing","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_42","first-page":"129259","article-title":"In-Depth Profiling of the Peripheral Blood Mononuclear Cells Proteome for Clinical Blood Proteomics","volume":"2014","author":"Kuhn","year":"2014","journal-title":"Int. J. Proteom."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ni.3693","article-title":"Social Network Architecture of Human Immune Cells Unveiled by Quantitative Proteomics","volume":"18","author":"Rieckmann","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrm3314","article-title":"Metabolomics: The Apogee of the Omics Trilogy","volume":"13","author":"Patti","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41467-020-17033-7","article-title":"Rapid, Deep and Precise Profiling of the Plasma Proteome with Multi-Nanoparticle Protein Corona","volume":"11","author":"Blume","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","article-title":"The Human Plasma Proteome","volume":"1","author":"Anderson","year":"2002","journal-title":"Mol. Cell. Proteom."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","article-title":"Plasma Proteome Profiling to Assess Human Health and Disease","volume":"2","author":"Geyer","year":"2016","journal-title":"Cell Syst."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"EMMM201910427","DOI":"10.15252\/emmm.201910427","article-title":"Plasma Proteome Profiling to Detect and Avoid Sample-related Biases in Biomarker Studies","volume":"11","author":"Geyer","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.jproteome.8b00903","article-title":"An Integrated Analysis of Metabolites, Peptides, and Inflammation Biomarkers for Assessment of Preanalytical Variability of Human Plasma","volume":"18","author":"Cao","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.21873\/cgp.20114","article-title":"A Comprehensive Proteome Analysis of Peripheral Blood Mononuclear Cells (PBMCs) to Identify Candidate Biomarkers of Pancreatic Cancer","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Genom. Proteom."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jprot.2012.07.012","article-title":"Proteome Signatures of Inflammatory Activated Primary Human Peripheral Blood Mononuclear Cells","volume":"76","author":"Klepeisz","year":"2012","journal-title":"J. Proteom."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","article-title":"Single-Pot, Solid-Phase-Enhanced Sample Preparation for Proteomics Experiments","volume":"14","author":"Hughes","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/pmic.201300553","article-title":"Suspension Trapping (STrap) Sample Preparation Method for Bottom-up Proteomics Analysis","volume":"14","author":"Zougman","year":"2014","journal-title":"Proteomics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1373\/clinchem.2012.199257","article-title":"Preanalytical Aspects and Sample Quality Assessment in Metabolomics Studies of Human Blood","volume":"59","author":"Yin","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00216-012-6039-y","article-title":"Current Trends and Challenges in Sample Preparation for Global Metabolomics Using Liquid Chromatography\u2013Mass Spectrometry","volume":"403","author":"Vuckovic","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: Neural Networks and Interference Correction Enable Deep Proteome Coverage in High Throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"O111.016717","DOI":"10.1074\/mcp.O111.016717","article-title":"Targeted Data Extraction of the MS\/MS Spectra Generated by Data-Independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis","volume":"11","author":"Gillet","year":"2012","journal-title":"Mol. Cell. Proteom."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1021\/ac0262560","article-title":"Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS\/MS","volume":"75","author":"Thompson","year":"2003","journal-title":"Anal. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nmeth.1714","article-title":"MS3 Eliminates Ratio Distortion in Isobaric Multiplexed Quantitative Proteomics","volume":"8","author":"Ting","year":"2011","journal-title":"Nat. Methods"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1021\/ac502040v","article-title":"MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes","volume":"86","author":"McAlister","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T Cell Metabolism Drives Immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Edwards-Hicks, J., Mitterer, M., Pearce, E.L., and Buescher, J.M. (2021). Metabolic Dynamics of In Vitro CD8+ T Cell Activation. Metabolites, 11.","DOI":"10.3390\/metabo11010012"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s42003-024-06339-7","article-title":"The Integration of Metabolic and Proteomic Data Uncovers an Augmentation of the Sphingolipid Biosynthesis Pathway during T-Cell Differentiation","volume":"7","author":"Kanno","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2024.02.009","article-title":"Acetyl-CoA Carboxylase Obstructs CD8+ T Cell Lipid Utilization in the Tumor Microenvironment","volume":"36","author":"Hunt","year":"2024","journal-title":"Cell Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.cmet.2025.07.006","article-title":"Glucose-Dependent Glycosphingolipid Biosynthesis Fuels CD8+ T Cell Function and Tumor Control","volume":"37","author":"Longo","year":"2025","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.copbio.2015.02.003","article-title":"A Roadmap for Interpreting 13C Metabolite Labeling Patterns from Cells","volume":"34","author":"Buescher","year":"2015","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum","volume":"332","author":"Bendall","year":"2011","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Iyer, A., Hamers, A.A.J., and Pillai, A.B. (2022). CyTOF\u00ae for the Masses. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.815828"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2018.03.055","article-title":"Metabolomics and Isotope Tracing","volume":"173","author":"Jang","year":"2018","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.xpro.2022.101174","article-title":"High-Dimensional Functional Phenotyping of Preclinical Human CAR T Cells Using Mass Cytometry","volume":"3","author":"Michelozzi","year":"2022","journal-title":"STAR Protoc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm.2375","article-title":"A Clinical Microchip for Evaluation of Single Immune Cells Reveals High Functional Heterogeneity in Phenotypically Similar T Cells","volume":"17","author":"Ma","year":"2011","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-017-0293-7","article-title":"Single-Cell Multiplexed Cytokine Profiling of CD19 CAR-T Cells Reveals a Diverse Landscape of Polyfunctional Antigen-Specific Response","volume":"5","author":"Xue","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e10798","DOI":"10.15252\/msb.202110798","article-title":"Ultra-high Sensitivity Mass Spectrometry Quantifies Single-cell Proteome Changes upon Perturbation","volume":"18","author":"Brunner","year":"2022","journal-title":"Mol. Syst. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13059-018-1547-5","article-title":"SCoPE-MS: Mass Spectrometry of Single Mammalian Cells Quantifies Proteome Heterogeneity during Cell Differentiation","volume":"19","author":"Budnik","year":"2018","journal-title":"Genome Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly Multiplexed Imaging of Tumor Tissues with Subcellular Resolution by Mass Cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat. Methods"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nm.3488","article-title":"Multiplexed Ion Beam Imaging of Human Breast Tumors","volume":"20","author":"Angelo","year":"2014","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1074\/mcp.M800540-MCP200","article-title":"Multiple Reaction Monitoring-Based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma","volume":"8","author":"Kuzyk","year":"2009","journal-title":"Mol. Cell. Proteom."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1074\/mcp.O112.020131","article-title":"Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics","volume":"11","author":"Peterson","year":"2012","journal-title":"Mol. Cell. Proteom."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"28566","DOI":"10.3390\/ijms161226120","article-title":"Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry","volume":"16","author":"Rauniyar","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1074\/mcp.O114.043968","article-title":"Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM)","volume":"14","author":"Gallien","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.56530\/lcgc.na.ii3372s8","article-title":"Analysis of Lipid Nanoparticles","volume":"41","author":"Auclair","year":"2023","journal-title":"LCGC Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A Careful Look at Lipid Nanoparticle Characterization: Analysis of Benchmark Formulations for Encapsulation of RNA Cargo Size Gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_86","unstructured":"Waters Corporation (2026, April 06). Characterization of Intact mRNA Using Ion Pair-Reversed Phase-Time of Flight-MS, Size Exclusion Chromatography-Multi Angle Light Scattering, and Charge Detection Mass Spectrometry. Available online: https:\/\/www.waters.com\/nextgen\/us\/en\/library\/library-details.html?documentid=PSTR135098898&t=waters-CharacterizationofIntactmRNAUsingIonPairReversedPhaseTimeofFlightMS-PSTR135098898."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"15717","DOI":"10.1021\/acs.analchem.5c01407","article-title":"Ion-Pairing Hydrophilic Interaction Chromatography for Impurity Profiling of Therapeutic Phosphorothioated Oligonucleotides","volume":"97","author":"Ferguson","year":"2025","journal-title":"Anal. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1021\/acs.analchem.2c03030","article-title":"Top-Down Mass Spectrometry of Synthetic Single Guide Ribonucleic Acids Enabled by Facile Sample Clean-Up","volume":"95","author":"Crittenden","year":"2023","journal-title":"Anal. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9430","DOI":"10.1021\/acs.analchem.5c00705","article-title":"Ion Mobility Gas-Phase Separation Enhances Top-Down Mass Spectrometry of Heavily Modified Guide RNA","volume":"97","author":"Macias","year":"2025","journal-title":"Anal. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1021\/acs.analchem.5c04150","article-title":"High-Resolution Ion Mobility Mass Spectrometry for Separation of Oligonucleotide Phosphorothioate Diastereomers","volume":"98","author":"Blevins","year":"2026","journal-title":"Anal. Chem."},{"key":"ref_91","first-page":"15304","article-title":"Diastereomer Characterization of PS-Modified Synthetic Oligonucleotides Using Cyclic IMS-MS","volume":"96","author":"Sharon","year":"2024","journal-title":"Anal. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1021\/acs.analchem.6c00816","article-title":"Quantitation of Diastereomer Content in PS-Modified Synthetic Oligonucleotides Using cIMS-MS","volume":"98","author":"Sharon","year":"2026","journal-title":"Anal. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1021\/acs.analchem.6c00747","article-title":"Analytical Assessment of sgRNA Impurities and Their Impact on Functional Performance","volume":"98","author":"Chatla","year":"2026","journal-title":"Anal. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Menneteau, T., Addepalli, B., Johnston, T., Reidy, C., Gorton, M., Bouchenna, J., Pittman, N., Butr\u00e9, C.I., Mouvet, D., and Denbigh, L. (2026, June 01). Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping|LCGC International. Available online: https:\/\/www.chromatographyonline.com\/view\/advancing-gene-therapy-enzyme-selection-for-effective-rna-oligonucleotide-mapping.","DOI":"10.56530\/lcgc.int.nv8977m6"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1039\/D4AN01155D","article-title":"Stationary Phase Effects in Hydrophilic Interaction Liquid Chromatographic Separation of Oligonucleotides","volume":"150","author":"Abernathy","year":"2024","journal-title":"Analyst"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chroma.2019.02.016","article-title":"Oligonucleotide Analysis by Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry in the Absence of Ion-Pair Reagents","volume":"1595","author":"Lobue","year":"2019","journal-title":"J. Chromatogr. A"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Camperi, J., Chatla, K., Freund, E., Galan, C., Lippold, S., and Guilbaud, A. (2025). Current Analytical Strategies for mRNA-Based Therapeutics. Molecules, 30.","DOI":"10.3390\/molecules30071629"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1021\/acs.analchem.9b01664","article-title":"Oligonucleotide Sequence Mapping of Large Therapeutic mRNAs via Parallel Ribonuclease Digestions and LC-MS\/MS","volume":"91","author":"Jiang","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00216-017-0840-6","article-title":"Poly A Tail Length Analysis of in Vitro Transcribed mRNA by LC-MS","volume":"410","author":"Beverly","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"118309","DOI":"10.1016\/j.trac.2025.118309","article-title":"Exploring the Potential of Oligonucleotide Mapping with Liquid Chromatography\u2014Mass Spectrometry to Study the Primary Structure of mRNA","volume":"191","author":"Maurer","year":"2025","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"465724","DOI":"10.1016\/j.chroma.2025.465724","article-title":"Characterisation and Analysis of mRNA Critical Quality Attributes Using Liquid Chromatography Based Methods","volume":"1745","author":"Webb","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Camperi, J., Freund, E., Galan, C., and Guilbaud, A. (2025). Establishing Analytical Methods for RNA-Based Therapeutics Characterization. Characterizing Biotherapeutics, John Wiley & Sons, Ltd.","DOI":"10.1002\/9781394236145.ch13"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e4465","DOI":"10.1002\/jms.4465","article-title":"High-Resolution Ion Mobility Spectrometry-Mass Spectrometry of Isomeric\/Isobaric Ribonucleotide Variants","volume":"55","author":"Kenderdine","year":"2020","journal-title":"J. Mass Spectrom."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.analchem.3c05539","article-title":"Comprehensive Impurity Profiling of mRNA: Evaluating Current Technologies and Advanced Analytical Techniques","volume":"96","author":"Camperi","year":"2024","journal-title":"Anal. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"17789","DOI":"10.1021\/acs.analchem.4c04162","article-title":"Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses","volume":"96","author":"Camperi","year":"2024","journal-title":"Anal. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1021\/acs.analchem.9b00062","article-title":"Native and Denaturing MS Protein Deconvolution for Biopharma: Monoclonal Antibodies and Antibody\u2013Drug Conjugates to Polydisperse Membrane Proteins and Beyond","volume":"91","author":"Campuzano","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"18984","DOI":"10.1039\/D5RA08835F","article-title":"Gauging Lipid Vulnerabilities in mRNA-LNPs under Various Environmental Stressors through TIMS-TOF Analysis","volume":"16","author":"Girgis","year":"2026","journal-title":"RSC Adv."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"123780","DOI":"10.1016\/j.talanta.2022.123780","article-title":"Comprehensive UHPLC- and CE-Based Methods for Engineered Cas9 Characterization","volume":"252","author":"Camperi","year":"2023","journal-title":"Talanta"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"14170","DOI":"10.1021\/acs.analchem.9b03808","article-title":"Multi-Attribute Method for Quality Control of Therapeutic Proteins","volume":"91","author":"Rogstad","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zhdanova, P.V., Chernonosov, A.A., Prokhorova, D.V., Stepanov, G.A., Kanazhevskaya, L.Y., and Koval, V.V. (2022). Probing the Dynamics of Streptococcus Pyogenes Cas9 Endonuclease Bound to the sgRNA Complex Using Hydrogen-Deuterium Exchange Mass Spectrometry. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031129"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00253-024-13056-y","article-title":"Engineering Cas9: Next Generation of Genomic Editors","volume":"108","author":"Kovalev","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/acs.analchem.1c04795","article-title":"Physicochemical and Functional Characterization of Differential CRISPR-Cas9 Ribonucleoprotein Complexes","volume":"94","author":"Camperi","year":"2022","journal-title":"Anal. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13361-016-1545-3","article-title":"Native Mass Spectrometry: What Is in the Name?","volume":"28","author":"Leney","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nchem.1889","article-title":"The Power of Ion Mobility-Mass Spectrometry for Structural Characterization and the Study of Conformational Dynamics","volume":"6","author":"Lanucara","year":"2014","journal-title":"Nat. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41594-018-0147-0","article-title":"Cross-Linking Mass Spectrometry: Methods and Applications in Structural, Molecular and Systems Biology","volume":"25","author":"Rappsilber","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41587-022-01418-8","article-title":"High-Yield Genome Engineering in Primary Cells Using a Hybrid ssDNA Repair Template and Small-Molecule Cocktails","volume":"41","author":"Shy","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1021\/jasms.4c00222","article-title":"Compaction, Relaxation, and Linearization of Megadalton-Sized DNA Plasmids: DNA Structures Probed by CD-MS","volume":"35","author":"Miller","year":"2024","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1242454","DOI":"10.1126\/science.1242454","article-title":"Fueling Immunity: Insights into Metabolism and Lymphocyte Function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"key":"ref_119","unstructured":"Repligen Corporation (2026, June 15). PATsmartTM MAVEN\u00ae Online Glucose and Lactate Monitoring. Available online: https:\/\/www.repligen.com\/maven."},{"key":"ref_120","unstructured":"908 Devices (2026, June 30). 908 Devices Launches the Rebel, the First At-Line Spent Cell Media Analyzer for Bioprocess Labs. Available online: https:\/\/908devices.com\/news\/908-devices-launches-the-rebel-the-first-at-line-spent-cell-media-analyzer-for-bioprocess-labs\/."},{"key":"ref_121","unstructured":"Repligen Corporation (2026, June 15). PATsmart REBEL XT At-Line Media Analyzer. Available online: https:\/\/www.repligen.com\/rebelxt."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jcyt.2023.03.010","article-title":"Early Detection and Metabolic Pathway Identification of T Cell Activation by In-Process Intracellular Mass Spectrometry","volume":"25","author":"Culberson","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1074\/mcp.M700354-MCP200","article-title":"Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution","volume":"6","author":"Keshishian","year":"2007","journal-title":"Mol. Cell. Proteom."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.1232578","article-title":"Direct Proteomic Quantification of the Secretome of Activated Immune Cells","volume":"340","author":"Meissner","year":"2013","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14789450.2017.1319768","article-title":"Mass Spectrometry-Based Proteomic Exploration of the Human Immune System: Focus on the Inflammasome, Global Protein Secretion, and T Cells","volume":"14","author":"Nyman","year":"2017","journal-title":"Expert Rev. Proteom."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"100217","DOI":"10.1016\/j.mcpro.2022.100217","article-title":"Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression","volume":"21","author":"Byrnes","year":"2022","journal-title":"Mol. Cell. Proteom."},{"key":"ref_127","unstructured":"European Medicines Agency (2026, June 02). Questions and Answers on Comparability Considerations for Advanced Therapy Medicinal Products (ATMP)\u2014Scientific Guideline|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/questions-and-answers-comparability-considerations-advanced-therapy-medicinal-products-atmp-scientific-guideline."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1021\/acs.jproteome.1c00887","article-title":"A Sensitive and Controlled Data-Independent Acquisition Method for Proteomic Analysis of Cell Therapies","volume":"21","author":"Pohl","year":"2022","journal-title":"J. Proteome Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"eaap9777","DOI":"10.1126\/scisignal.aap9777","article-title":"An Immunoproteomic Approach to Characterize the CAR Interactome and Signalosome","volume":"12","author":"Ramello","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic Analysis of Chimeric Antigen Receptor Signaling Reveals Kinetic and Quantitative Differences That Affect Cell Function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Dakup, P.P., Feng, S., Shi, T., Jacobs, J.M., Wiley, H.S., and Qian, W.-J. (2023). Targeted Quantification of Protein Phosphorylation and Its Contributions towards Mathematical Modeling of Signaling Pathways. Molecules, 28.","DOI":"10.3390\/molecules28031143"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1038\/s41467-023-43656-7","article-title":"CAR+ and CAR\u2212 T Cells Share a Differentiation Trajectory into an NK-like Subset after CD19 CAR T Cell Infusion in Patients with B Cell Malignancies","volume":"14","author":"Louie","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-Cell CAR T Atlas Reveals Type 2 Function in 8-Year Leukaemia Remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41467-026-69857-4","article-title":"Immunometabolic Determinants of Long-Term Response in Leukemia Patients Receiving CD19 CAR T Cell Therapy","volume":"17","author":"Goldberg","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.ymthe.2019.06.001","article-title":"Fresh versus Frozen: Effects of Cryopreservation on CAR T Cells","volume":"27","author":"Hanley","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11626-017-0201-y","article-title":"Best Practices for Cryopreserving, Thawing, Recovering, and Assessing Cells","volume":"53","author":"Baust","year":"2017","journal-title":"Vitr. Cell. Dev. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00216-021-03648-2","article-title":"Monitoring Process-Related Impurities in Biologics\u2013Host Cell Protein Analysis","volume":"414","author":"Pilely","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/19420862.2015.1069454","article-title":"Development of a Quantitative Mass Spectrometry Multi-Attribute Method for Characterization, Quality Control Testing and Disposition of Biologics","volume":"7","author":"Rogers","year":"2015","journal-title":"mAbs"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/s12248-017-0168-3","article-title":"A View on the Importance of \u201cMulti-Attribute Method\u201d for Measuring Purity of Biopharmaceuticals and Improving Overall Control Strategy","volume":"20","author":"Rogers","year":"2017","journal-title":"AAPS J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.aca.2019.01.043","article-title":"Tutorial on Lipidomics","volume":"1061","author":"Wang","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.jlr.2021.100138","article-title":"Recommendations for Good Practice in MS-Based Lipidomics","volume":"62","author":"Ahrends","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor\u2013Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/pr034086h","article-title":"Mass Spectrometric Quantitation of Peptides and Proteins Using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA)","volume":"3","author":"Anderson","year":"2004","journal-title":"J. Proteome Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nmeth.2015","article-title":"Selected Reaction Monitoring\u2013Based Proteomics: Workflows, Potential, Pitfalls and Future Directions","volume":"9","author":"Picotti","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1021\/acs.jproteome.9b00320","article-title":"Stability of the Human Plasma Proteome to Pre-Analytical Variability as Assessed by an Aptamer-Based Approach","volume":"18","author":"Daniels","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_149","unstructured":"FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and Other Tools) Resource."},{"key":"ref_150","unstructured":"U.S. Food and Drug Administration (2026, June 08). M10 Bioanalytical Method Validation and Study Sample Analysis, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:30:13Z","timestamp":1785115813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":150,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151333"],"URL":"https:\/\/doi.org\/10.3390\/cells15151333","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}